From MSO asset purchases to physician equity rollovers, here is how buyers and sellers structure transactions in the IVF and reproductive medicine space — and what each approach means for your outcome.
Acquiring or selling a fertility clinic is not a straightforward business transaction. The corporate practice of medicine doctrine in most states prohibits non-physicians from directly owning a medical practice, which means deal structures must work around this legal framework while still delivering value to both sides. The most common solution is a Management Services Organization — or MSO — structure, where a buyer acquires the business operations and assets while the physician entity retains nominal clinical ownership and enters into a long-term Professional Services Agreement. On top of this legal complexity, fertility clinics carry significant key-person risk tied to the founding reproductive endocrinologist, making transition mechanics — earnouts, equity rollovers, and employment agreements — critical negotiating points. Deals in this space typically close at 5x to 9x EBITDA depending on SART success rates, laboratory quality, physician depth, and payer mix. Understanding the structure before you negotiate is the difference between a smooth transition and a deal that collapses at closing.
Find Fertility Clinic Businesses For SaleMSO Asset Purchase with Professional Services Agreement
The buyer acquires all non-clinical assets of the fertility clinic — including equipment, patient records, contracts, goodwill, and real estate or leasehold interests — through a Management Services Organization entity. A separately licensed physician professional corporation or PC retains clinical operations and enters into a long-term Professional Services Agreement with the MSO. The buyer controls economics through the PSA while remaining compliant with state corporate practice of medicine laws.
Pros
Cons
Best for: Private equity-backed fertility networks, regional platform builders, or strategic acquirers such as US Fertility or Inception Fertility acquiring an independent physician-owned IVF clinic in a corporate practice of medicine state.
Equity Recapitalization with Physician Rollover
A private equity buyer or fertility network acquires a majority equity stake — typically 60 to 80 percent — in the practice's holding or management entity, while the founding reproductive endocrinologist retains 20 to 40 percent equity. The physician rolls their retained equity into the acquiring platform, aligning incentives for post-close growth. Earnout provisions tied to patient volume, IVF cycle counts, or EBITDA growth over 3 to 5 years are typically layered on top of the upfront payment.
Pros
Cons
Best for: Founder reproductive endocrinologists who are 50 to 60 years old, still clinically active, and want immediate liquidity while participating in upside as the platform scales. Ideal when the clinic is the acquirer's platform entry into a new geography.
Full Acquisition with Seller-Financed Note
The buyer purchases 100 percent of the practice through an asset or equity purchase, with the seller carrying back a subordinated promissory note representing 10 to 20 percent of the total purchase price. The note is typically held for 2 to 3 years at a fixed interest rate of 6 to 8 percent and is often contingent on physician transition milestones, patient retention thresholds, or EBITDA performance during the note period.
Pros
Cons
Best for: Physician sellers approaching retirement (ages 60 to 70) who want a clean exit with a defined transition period, are willing to provide seller financing to close the gap between buyer and seller price expectations, and have an associate RE capable of sustaining patient volume post-close.
Private Equity Platform Acquires Established Multi-Physician IVF Clinic
$12,000,000
$8,400,000 paid at closing as MSO asset purchase price (70%); $2,400,000 in rollover equity representing 20% stake in the acquiring platform entity; $1,200,000 earnout tied to IVF cycle volume and EBITDA thresholds over 36 months (10%)
Founding RE signs 5-year employment agreement at market-rate compensation plus performance bonus; rollover equity vests over 3 years with tag-along rights at platform exit; earnout measured annually against a baseline of 420 IVF cycles and $2.2M EBITDA; MSO PSA structured as a 40-year exclusive management agreement with the physician PC
Entrepreneurial Physician Acquires Single-RE Clinic with Seller Financing
$4,500,000
$3,600,000 paid at closing through a combination of buyer equity ($1,800,000) and a bank or private credit facility ($1,800,000); $900,000 seller-financed promissory note at 7% annual interest over 30 months
Seller stays on as a contracted clinical consultant for 18 months at $12,000 per month to facilitate patient and referral transitions; seller note is released in full if EBITDA exceeds $1.1M in the first 24 months post-close; note subordinated to senior lender with a 90-day cure period for any covenant breach; buyer assumes CLIA, SART, and state licensure obligations at closing
Regional Health System Adds Fertility Service Line via Full Equity Acquisition
$7,200,000
$7,200,000 paid entirely in cash at closing with no earnout or rollover; health system absorbs the practice into its employed physician group under a standard health system employment agreement
Both reproductive endocrinologists converted to health system employees at blended compensation of $480,000 per physician annually; clinic rebranded under health system name within 6 months; IVF laboratory undergoes health system accreditation review within 90 days of close; seller provides 12-month post-close clinical availability warranty with a $300,000 clawback for SART outcome deterioration in year one
Find Fertility Clinic Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
Most states prohibit non-physician entities from directly owning a medical practice under corporate practice of medicine laws. Because reproductive endocrinologists must hold a medical license to provide ART services, the clinical practice must technically be owned by a licensed physician or physician group. Private equity buyers solve this through an MSO structure — they own the management company that controls all non-clinical assets and economics, while a physician PC retains nominal clinical ownership and operates under a long-term Professional Services Agreement with the MSO.
Fertility clinics with strong SART success rates, multiple reproductive endocrinologists, and an in-house accredited IVF laboratory typically trade at 6x to 9x EBITDA. Single-physician practices or clinics with below-average published outcomes may trade at 5x to 6x. The specific multiple depends on physician depth, payer mix, laboratory quality, revenue diversification across services like egg freezing and PGT, and whether the clinic holds existing employer fertility benefit contracts with platforms like Progyny or WINFertility.
An earnout is a contingent payment where the buyer pays additional consideration after closing if the practice hits defined performance milestones — typically IVF cycle volume or EBITDA targets over 2 to 5 years. Earnouts make sense when the buyer and seller disagree on how much of the clinic's value is tied to the founding physician personally. If the seller believes patients will stay and the buyer is skeptical, an earnout lets both parties bet on that outcome. For fertility clinics specifically, earnouts are most common in equity recapitalizations where the founding RE retains a minority stake and has skin in the game.
SART membership and annual CDC ART success rate reporting are material to a fertility clinic's value and transferability. Buyers will review the last 3 to 5 years of SART-reported outcomes and benchmark them against national averages. Clinics with consistently above-average live birth rates command premium multiples. Any history of adverse CDC reports, corrective actions, or SART data quality issues creates significant due diligence risk and will be reflected in the purchase price or deal structure through escrow holdbacks and indemnification provisions.
CLIA certification is tied to the physical laboratory location and the laboratory director — not the legal ownership entity. In most acquisitions, the buyer must apply for a new CLIA certificate or modify the existing one, and ensure a board-certified embryologist or qualified laboratory director is in place to maintain accreditation. This process takes time and must be coordinated with the state health department. Buyers should include a pre-close CLIA transition plan in their due diligence checklist and confirm that no accreditation lapses occur during the ownership transfer period.
Rollover equity can significantly increase a seller's total exit proceeds if the acquiring platform is well-capitalized and has a credible exit strategy. A founder RE who rolls 20 to 30 percent of their sale proceeds into a PE-backed fertility platform at a 7x EBITDA multiple could participate in a second exit at 10x or higher if the platform scales successfully over 5 to 7 years. The risk is illiquidity — rollover equity cannot be sold until the platform exits, and there is no guarantee the platform achieves a premium multiple. Sellers should evaluate the acquirer's track record, portfolio quality, and fund vintage before accepting rollover as a material portion of their consideration.
More Fertility Clinic Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers